Eisai’s Leqembi unlocks at-home dosing with FDA autoinjector approval
The US Food and Drug Administration (FDA) has approved a once-weekly autoinjector version of Eisai’s Alzheimer’s drug Leqembi (lecanemab), as…
The US Food and Drug Administration (FDA) has approved a once-weekly autoinjector version of Eisai’s Alzheimer’s drug Leqembi (lecanemab), as…
Amylyx Pharmaceuticals has discontinued a clinical programme evaluating a neuronal cell death inhibitor as a result of disappointing data when tested…
Apertura Gene Therapy has entered several licensing agreements to advance central nervous system (CNS) treatments using its transferrin receptor 1…
Biostar Stem Cell Technology Research Institute has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for its…
The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents,…
Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, Supernus and Sage entered a definitive…
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular…
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery…
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor…
Niagen Bioscience has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital, Bergen, Norway, for the development of…